Versartis, Inc. (NASDAQ:VSAR) Director Srinivas Akkaraju bought 513,872 shares of the stock in a transaction on Monday, December 4th. The stock was purchased at an average price of $2.21 per share, for a total transaction of $1,135,657.12. Following the completion of the purchase, the director now directly owns 14,955 shares in the company, valued at $33,050.55. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Srinivas Akkaraju also recently made the following trade(s):
- On Friday, December 1st, Srinivas Akkaraju bought 419,700 shares of Versartis stock. The stock was purchased at an average price of $2.13 per share, for a total transaction of $893,961.00.
Shares of Versartis, Inc. (VSAR) remained flat at $$2.02 during trading hours on Wednesday. The company’s stock had a trading volume of 909,500 shares, compared to its average volume of 814,079. Versartis, Inc. has a 1-year low of $1.60 and a 1-year high of $24.00. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52.
Several analysts have recently weighed in on VSAR shares. Morgan Stanley restated an “equal weight” rating and set a $4.00 price objective (up previously from $3.00) on shares of Versartis in a research report on Friday, September 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $14.00 price objective (down previously from $34.00) on shares of Versartis in a research report on Friday, September 22nd. Piper Jaffray Companies restated a “buy” rating and set a $26.00 price objective on shares of Versartis in a research report on Friday, September 8th. Cowen cut shares of Versartis from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $45.00 to $3.00 in a research report on Friday, September 22nd. Finally, Bank of America cut shares of Versartis from a “buy” rating to a “neutral” rating in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $7.22.
Large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its position in Versartis by 46.3% in the 1st quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 3,001 shares during the period. Tudor Investment Corp ET AL purchased a new position in Versartis in the 2nd quarter worth $218,000. Numeric Investors LLC purchased a new position in Versartis in the 2nd quarter worth $246,000. Voya Investment Management LLC raised its position in Versartis by 26.1% in the 2nd quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 3,094 shares during the period. Finally, State of Wisconsin Investment Board purchased a new position in Versartis in the 2nd quarter worth $419,000. Institutional investors own 49.18% of the company’s stock.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
What are top analysts saying about Versartis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Versartis Inc. and related companies.